Merck Mevacor Exclusivity Will Run Until Dec. 15 Following FDA Reversal

FDA is granting Merck pediatric exclusivity for Mevacor (lovastatin) through Dec. 15 following consideration of clarified data submitted by the company.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet